Abstract:Arteriosclerosis, Thrombosis, and Vascular Biology, Ahead of Print. Cardiovascular disease (CVD) remains a major health burden despite significant therapeutic advances accomplished over the last decades. It is widely and increasingly recognized that systemic inflammation not only represents a major cardiovascular risk and prognostic factor but also plays pivotal roles in CVD development and progression. Despite compelling preclinical evidence suggesting large potential of anti-inflammatory pharmacological interventions across numerous CVDs, clinical translation remains incomplete, mainly due to (1) yet undefined molecular signaling; (2) challenges of safety and efficacy profile of anti-inflammatory drugs; and (3) difficulties in identifying optimal patient candidates and responders to anti-inflammatory therapeutics, as well as optimal therapeutic windows. Randomized controlled trials demonstrated the safety/efficacy of canakinumab and colchicine in secondary cardiovascular prevention, providing confirmation for the involvement of a specific inflammatory pathway (NLRP3 [NACHT, LRR, and PYD domain-containing protein 3] inflammasome/IL [interleukin]-1β) in atherosclerotic CVD. Colchicine was recently approved by the US Food and Drug Administration for this indication. Diverse anti-inflammatory drugs targeting distinct inflammatory pathways are widely used for the management of other CVDs including myocarditis and pericarditis. Ongoing research efforts are directed to implementing anti-inflammatory therapeutics across a growing number of CVDs, through repurposing of available anti-inflammatory drugs and development of novel anti-inflammatory compounds, which are herein concisely discussed. This review also summarizes the main characteristics and findings of completed and upcoming randomized controlled trials directly targeting inflammation in CVDs and discusses the major challenges and future perspectives in the exciting and constantly expanding landscape of cardioimmunology.

Inflammation as a New Therapeutic Target among Older Patients with Ischemic Heart Disease

Novel Therapeutics and Upcoming Clinical Trials Targeting Inflammation in Cardiovascular Diseases

Inflammation in heart failure: pathophysiology and therapeutic strategies

Inflammaging: Mechanisms and Role in the Cardiac and Vasculature

Recent Progress in Vascular Aging: Mechanisms and Its Role in Age-related Diseases

Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment

Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions

Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets

Cardiovascular disease in the elderly: proceedings of the European Society of Cardiology-Cardiovascular Round Table

Inflammation and Cardiovascular Disease: The Future

Anti-ageing interventions for the treatment of cardiovascular disease

Inflammation and aging-related disease: A transdisciplinary inflammaging framework

Inflammation as A Precursor of Atherothrombosis, Diabetes and Early Vascular Aging

Inflammatory Molecular Mediators and Pathways Involved in Vascular Aging and Stroke: A Comprehensive Review

Targeting Inflammation to Reduce Residual Cardiovascular Risk

Targeting endothelial dysfunction and inflammation

Emerging Trends and Innovations in the Treatment and Diagnosis of Atherosclerosis and Cardiovascular Disease: A Comprehensive Review towards Healthier Aging

Chronological vs Biological Age in Interventional Cardiology: A Comprehensive Approach to Care for Older Adults: JACC Family Series

Inflammation, Oxidative Stress, Senescence in Atherosclerosis: Thioredoxine-1 as an Emerging Therapeutic Target

Age related issues in reperfusion of myocardial infarction

New Insights in Cardiac β-Adrenergic Signaling During Heart Failure and Aging